BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 30396570)

  • 1. Imatinib mesylate elicits extracellular signal-related kinase (ERK) activation and enhances the survival of γ-irradiated epithelial cells.
    Lee J; Ko J; Kim HJ; Im H; Kim EJ; Yi JY
    Biochem Biophys Res Commun; 2018 Dec; 506(4):939-943. PubMed ID: 30396570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
    Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
    Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
    Fred RG; Boddeti SK; Lundberg M; Welsh N
    Clin Sci (Lond); 2015 Jan; 128(1):17-28. PubMed ID: 24865476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
    Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
    Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular signal-regulated kinase activation delays hyperoxia-induced epithelial cell death in conditions of Akt downregulation.
    Truong SV; Monick MM; Yarovinsky TO; Powers LS; Nyunoya T; Hunninghake GW
    Am J Respir Cell Mol Biol; 2004 Dec; 31(6):611-8. PubMed ID: 15308507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
    Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
    Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-thermal atmospheric pressure plasma-induced IL-8 expression is regulated via intracellular K
    Hotta E; Hara H; Kamiya T; Adachi T
    Arch Biochem Biophys; 2018 Apr; 644():64-71. PubMed ID: 29518371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release.
    Kumar P; Coltas IK; Kumar B; Chepeha DB; Bradford CR; Polverini PJ
    Cancer Res; 2007 Feb; 67(3):1193-202. PubMed ID: 17283155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate causes hypopigmentation in the skin.
    Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
    Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
    Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
    PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the extracellular signal-regulated kinase (ERK) pathway and the induction of radioresistance in rat 3Y1 cells.
    Watanabe H; Kurabayashi T; Miura M
    Int J Radiat Biol; 2004 Jun; 80(6):451-7. PubMed ID: 15362698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.